Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Biologics License Application for cosibelimab under review by U.S. FDA

PDUFA goal date of December 28, 2024

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates.

Read more at globenewswire.com